Evidence map›Paper›PMID 29209859›Full record

Trial reportWiener medizinische Wochenschrift (1946)2019

Spicae aetheroleum in uncomplicated acute bronchitis: a double-blind, randomised clinical trial.

Christian Kähler, Tadeusz Derezinski, Joanna Bocian-Sobkowska, Andrea Keckeis, Gabriele Zacke

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Wiener medizinische Wochenschrift (1946), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07518394 (Using Botanical Ingestible Oils for Treating Infectious Conditions), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07518394 phase4completednot on this mapstarted 2023, after this paper: background citation

Using Botanical Ingestible Oils for Treating Infectious Conditions: The UBIOTIC Study on Essential Oils for Lower Respiratory Infections in the Emergency Department

TypeinterventionalSponsorUniversity of SfaxRan2023 to 2024Enrolled105ConditionsRespiratory InflammationArmsessential oils of eucalyptus, thyme, cinnamon, lavender, winter savory, tea tree, camphor tree, placebo of the essential oil capsule
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety of AtusinBMC pulmonary medicine · 2025
    Trial
  3. Review
  4. Review
  5. Article
  6. Lavender (Avicenna journal of phytomedicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christian KählerDepartment for Pneumology, Critical Care and Allergology, Wangen im Allgäu, Germany.
Tadeusz DerezinskiMedical Centre ESCULAP, Gniewkowo, Poland.
Joanna Bocian-SobkowskaMedical Centre BONUS, Skorzewo, Poland.
Andrea KeckeisMedical Centre Bludenz, Bludenz, Austria.
Gabriele ZackePharmazeutische Fabrik Montavit Ges.m.b.H., Absam, Austria. gabriele.zacke@montavit.com.
Landwirtschaftlichen Zentrums Baden-Württemberg​ · DEMontavit (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe trial aimed to evaluate the efficacy and safety of Spicae aetheroleum (Spicae ae.), a phytomedicine obtained by steam distillation of the flowering tops of Lavandula latifolia, as compared to placebo in adult patients with acute bronchitis.

methodsPatients with uncomplicated acute bronchitis (bronchitis severity score [BSS] ≥ 5 score points) were randomly assigned to treatment with Spicae ae. or placebo in a double-blind, parallel-group design. No additional treatment was admitted. The primary objective was the mean difference of a defined total BSS of 25% between the Spicae ae. and the placebo group after 7 days of full medication dose. Secondary endpoints included the BSS at day 10, additional signs and symptoms of bronchitis, quality of life (QoL) and safety.

resultsThe mean decrease in BSS at day 7 and day 10 was significant with 4.79 vs. 3.20 (p < 0.005 for a 25% difference) and 6.47 vs. 4.32 (p < 0.009 for a 25% difference) score points respectively in the Spicae ae. (n = 119) vs. placebo group (n = 110). Accordingly, most additional signs and symptoms of acute bronchitis as well as the patients' QoL improved significantly with Spicae ae. as compared to placebo. In all, 258 patients were eligible for safety analysis. The treatment with Spicae ae. was well tolerated; no serious adverse events occurred.

conclusionThe defined objectives both for the primary and secondary endpoints have been met. The results of this study provide evidence that Spicae ae. is well tolerated, effective and superior to placebo in the symptomatic treatment of uncomplicated acute bronchitis in adult patients.

Indexed as

BronchitisQuality of LifeAdolescentAdultAgedDouble-Blind MethodFemaleHumansLavandulaMaleMiddle AgedPhytotherapyPlant ExtractsTreatment OutcomeYoung AdultPlant ExtractsCoughLavandulaLinaloolPatient safetyPlant preparations

Identifiers

PMID29209859
PMCPMC6435634
OpenAlexW2773378611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.